Coronavirus | Covishield shelf life extended to 9 months, shows document

AstraZeneca said in a statement last week that its product could be stored, transported and handled at normal refrigerated conditions for at least six months.

March 30, 2021 08:49 pm | Updated March 31, 2021 02:01 am IST - New Delhi

A medical staff seen holding Covishield vaccine dose for vaccinating at the Rajiv Gandhi Super Speciality Hospital in New Delhi on Tuesday, March 02, 2021.

A medical staff seen holding Covishield vaccine dose for vaccinating at the Rajiv Gandhi Super Speciality Hospital in New Delhi on Tuesday, March 02, 2021.

India’s drug regulator has allowed the AstraZeneca COVID-19 vaccine to be used for up to nine months from its manufacture date, as opposed to the prescribed six months, according to a document reviewed by Reuters. A source confirmed this.

The approval, given to a licensed version of the drug made by the Serum Institute of India (SII) and exported to dozens of countries, could help health authorities minimise vaccine wastage and better plan their inoculation programmes.

Some African countries have only until the middle of next month to use up more than a million doses of the vaccine — branded Covishield by SII — if the shelf life is not extended.

“You are permitted to apply the shelf life of 9 months to unlabelled vials available on hand,” Drugs Controller General of India V.G. Somani, wrote late last month in reply to a request from the SII.

AstraZeneca said in a statement last week that its product could be stored, transported and handled at normal refrigerated conditions for at least six months. The World Health Organization website also gives the shelf life of Covishield and the South Korean-made AstraZeneca shot as six months.

Reuters has reviewed Mr. Somani’s approval, which has been communicated to some African countries, but could not determine if his recommendation applied to unused vials. Each vial typically contains five millilitre of vaccine, or 10 doses.

A source, with direct knowledge of the matter but not authorised to discuss it publicly, said the approval was given based on data submitted by the SII. The source did not specify what kind of data was shared by the company, the world’s biggest vaccine maker.

Mr. Somani, the SII and AstraZeneca did not immediately respond to requests for comment.

India has so far administered 55 million Covishield doses at home and exported nearly 64 million. The country is also using Covaxin, a vaccine developed domestically by Bharat Biotech.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.